Emerging from a valuation of US$ 2.5 billion in 2022, the global clostridium diagnostics market is poised to ascend to US$ 7.8 billion by 2032, demonstrating a notable Compound Annual Growth Rate (CAGR) of 12.2% over the forecast period. Between 2015 and 2021, the market exhibited an even more robust CAGR of 13.6%. This remarkable growth in the market can be attributed to the escalating incidence of clostridium-related diseases and the heightened efforts in public awareness campaigns aimed at educating individuals about this condition.
There has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.
Click Here to Access Your Visuals-Packed Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15203
Awareness campaigns are expected to play important role in driving the market during the forecast period. For instance, the ‘See C. diff’ campaign, launched by Peggy Lillis Foundation in December 2020, attained its objective by reaching more than 250,000 Americans. The organization launched the ‘See C. diff’ to commemorate C.diff Awareness Month in 2019, and reached about 80,000 people.
The launch of new vaccines in the market is another vital factor driving the market during the forecast period. For instance, in August 2021, Huvepharma Canada Corporation Inc. launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens type A in broiler chickens.
In addition, emerging companies such as, Acurx Pharmaceuticals, Cubist Pharmaceuticals, Endo Aesthetics, Avisa Pharma, and MGB Bio Pharma are expected to make a significant contribution in developing the market during the forecast period. However, lack of awareness and scarcity of resources in developing countries are expected to hamper the market growth during the forecast period. Also, the high costs involved in R&D and vaccine manufacturing are expected to be other factors hindering the market growth in the assessment period.
However, growing partnerships among players are projected to counter the hampering factors and boost the market. For instance, in March 2021, Peggy Lillis Foundation for Clostridium difficile infections announced a partnership with Ferring Pharmaceutical through a new sponsorship to assist new and existing patient advocacy initiatives.
Key Takeaways from the Market Study:
- The immunoassays technology is expected to dominate the global clostridium diagnostics market at a CAGR of 11.6% during 2022-2032
- The clostridium diagnostics market in the U.S is anticipated to display a CAGR of 11.8% during the forecast period
- The U.K clostridium diagnostics market is predicted to hold a market value worth US$ 330 Million by 2032
- The Japanese clostridium diagnostics market is estimated at a CAGR of 11.1% during the forecast period.
“Growing launch of new vaccines by various players of the market along with the increasing popularity of awareness campaigns as a useful tool for market growth is expected to play a significant role in driving the market during the forecast period,” says an FMI analyst.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/15203
Competition Analysis
- Abbott Laboratories
- F. Hoffmann La-Roche AG
- Siemens AG
- Becton, Dickinson & Company
- Beckman Coulter Inc.
- Sysmex India Pvt. Ltd.
- Thermo Fisher Scientific Inc.
- Fujirebio US Inc.
- BioMerieux S.A
- Diazyme Laboratories Inc.
Key Segments Profiled In The Global Clostridium Diagnostics Market
Clostridium Diagnostics Market by Technology:
- Immunoassays-based Clostridium Diagnostics
- Molecular Clostridium Diagnostics
Clostridium Diagnostics Market by End User:
- Clostridium Diagnostics in Hospitals
- Clostridium Diagnostics in Government Diagnostics Laboratories
- Clostridium Diagnostics in Independent Laboratories
Clostridium Diagnostics Market by Product:
- Clostridium Difficile Diagnostics
- Clostridium Perfringens Diagnostics
- Clostridium Botulinum Diagnostics
- Clostridium Tetani Diagnostics
- Clostridium Sordell Diagnostics
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube